RT @VivekSubbiah: 16 b. Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer @CD_AA…
RT @VivekSubbiah: 16 b. Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer @CD_AA…
RT @VivekSubbiah: 16 b. Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer @CD_AA…
16 b. Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer @CD_AACR @ElizSMcKenna https://t.co/X6BOjQR2Qi
RT @mtrainier2021: 这个效果太牛了。10周后,肿瘤的体积缩小了近80%。论文见这个https://t.co/cbcE3iTXn5 https://t.co/O6okvXF3fB https://t.co/f1ANh6LGtw
stonks
From the July issue: Mobocertinib (TAK-788): A targeted inhibitor of #EGFR #exon20 insertion mutants in non-small cell #lungcancer. https://t.co/YmzyXgmqQV @TakedaOncology #NSCLC https://t.co/bYEDVDuKAa
RT @OncoAlert: The @OncoAlert 🚨 @CD_AACR Academic Recap Activity & Safety of TAK7⃣8⃣8⃣ in #NSCLC w/ #EGFR mutation🧬 Discussed by @OncoAl…
RT @OncoAlert: Dear friends at #AACR21 With all the great science being presented at @AACR why not check out some great papers out on @CD_A…
RT @OncoAlert: Dear friends at #AACR21 With all the great science being presented at @AACR why not check out some great papers out on @CD_A…
RT @OncoAlert: Dear friends at #AACR21 With all the great science being presented at @AACR why not check out some great papers out on @CD_A…
RT @OncoAlert: Dear friends at #AACR21 With all the great science being presented at @AACR why not check out some great papers out on @CD_A…
RT @OncoAlert: Dear friends at #AACR21 With all the great science being presented at @AACR why not check out some great papers out on @CD_A…
RT @OncoAlert: Dear friends at #AACR21 With all the great science being presented at @AACR why not check out some great papers out on @CD_A…
Dear friends at #AACR21 With all the great science being presented at @AACR why not check out some great papers out on @CD_AACR Here Our #OncoAlert Faculty member @StephenVLiu discusses Activity & Safety of TAK7⃣8⃣8⃣ in #NSCLC w/ #EGFR mutation🧬 CH
RT @Exon20Group: Superb 2 minute recap of mobocertinib highlights, @StephenVLiu! @Exon20Group hopes mobo will become/remain a very importa…
RT @Exon20Group: Superb 2 minute recap of mobocertinib highlights, @StephenVLiu! @Exon20Group hopes mobo will become/remain a very importa…
Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer https://t.co/n9oACfV3V3
RT @OncoAlert: New @OncoAlert 🚨 @CD_AACR Academic Recap coming in2⃣days. Dont for get to Catch @StephenVLiu discussing a great paper by @R…
RT @OncoAlert: New @OncoAlert 🚨 @CD_AACR Academic Recap coming in2⃣days. Dont for get to Catch @StephenVLiu discussing a great paper by @R…
RT @Exon20Group: Superb 2 minute recap of mobocertinib highlights, @StephenVLiu! @Exon20Group hopes mobo will become/remain a very importa…
RT @OncoAlert: New @OncoAlert 🚨 @CD_AACR Academic Recap coming in2⃣days. Dont for get to Catch @StephenVLiu discussing a great paper by @R…
RT @OncoAlert: New @OncoAlert 🚨 @CD_AACR Academic Recap coming in2⃣days. Dont for get to Catch @StephenVLiu discussing a great paper by @R…
RT @OncoAlert: New @OncoAlert 🚨 @CD_AACR Academic Recap coming in2⃣days. Dont for get to Catch @StephenVLiu discussing a great paper by @R…
RT @OncoAlert: New @OncoAlert 🚨 @CD_AACR Academic Recap coming in2⃣days. Dont for get to Catch @StephenVLiu discussing a great paper by @R…
RT @OncoAlert: New @OncoAlert 🚨 @CD_AACR Academic Recap coming in2⃣days. Dont for get to Catch @StephenVLiu discussing a great paper by @R…
RT @OncoAlert: New @OncoAlert 🚨 @CD_AACR Academic Recap coming in2⃣days. Dont for get to Catch @StephenVLiu discussing a great paper by @R…
RT @OncoAlert: New @OncoAlert 🚨 @CD_AACR Academic Recap coming in2⃣days. Dont for get to Catch @StephenVLiu discussing a great paper by @R…
New @OncoAlert 🚨 @CD_AACR Academic Recap coming in2⃣days. Dont for get to Catch @StephenVLiu discussing a great paper by @RielyMD & team on Activity &Safety of TAK788 in #NSCLC with #EGFR mutation THE PAPER IS FREE to download until MARCH 31,
RT @ElizSMcKenna: The first @OncoAlert - @CD_AACR Academic Recap is up!! @StephenVLiu discusses the recently published phase 1/2 trial of m…
RT @OncoReporte: No te pierdas esta nueva colaboración entre @OncoAlert 🚨 y nuestros amigos de @CD_AACR Esta semana hablamos #Cancer de p…
RT @minhantan: TAK-788 (mobocertinib) shows 43% response rate in Phase I/II dose escalation trial in patients with diverse EGFR exon 20 mut…
RT @jillfeldman4: Great summary by @StephenVLiu on TAK788 for people with #NSCLC #Exon20 #LCSM
RT @minhantan: TAK-788 (mobocertinib) shows 43% response rate in Phase I/II dose escalation trial in patients with diverse EGFR exon 20 mut…
RT @jillfeldman4: Great summary by @StephenVLiu on TAK788 for people with #NSCLC #Exon20 #LCSM https://t.co/PLwbE5cFJf
RT @DarcyBurbage: Ck out the latest collaboration from.@OncoAlert w/@StephenVLiu ! .@oncologynursing https://t.co/puH6rlDfsZ
RT @Exon20Group: Superb 2 minute recap of mobocertinib highlights, @StephenVLiu! @Exon20Group hopes mobo will become/remain a very importa…
RT @OncoAlert: The @OncoAlert 🚨 @CD_AACR Academic Recap Activity & Safety of TAK7⃣8⃣8⃣ in #NSCLC w/ #EGFR mutation🧬 Discussed by @OncoAl…
RT @OncoAlert: The @OncoAlert 🚨 @CD_AACR Academic Recap Activity & Safety of TAK7⃣8⃣8⃣ in #NSCLC w/ #EGFR mutation🧬 Discussed by @OncoAl…
RT @OncoAlert: The @OncoAlert 🚨 @CD_AACR Academic Recap Activity & Safety of TAK7⃣8⃣8⃣ in #NSCLC w/ #EGFR mutation🧬 Discussed by @OncoAl…
RT @jillfeldman4: Great summary by @StephenVLiu on TAK788 for people with #NSCLC #Exon20 #LCSM https://t.co/PLwbE5cFJf
RT @weoncologists: The @OncoAlert 🚨 @CD_AACR Academic Recap Great paper on #NSCLC by @RielyMD & Team Amazing Discussion by @StephenVLiu…
RT @Exon20Group: Superb 2 minute recap of mobocertinib highlights, @StephenVLiu! @Exon20Group hopes mobo will become/remain a very importa…
RT @weoncologists: The @OncoAlert 🚨 @CD_AACR Academic Recap Great paper on #NSCLC by @RielyMD & Team Amazing Discussion by @StephenVLiu…
RT @Exon20Group: Superb 2 minute recap of mobocertinib highlights, @StephenVLiu! @Exon20Group hopes mobo will become/remain a very importa…
RT @OncoAlert: The @OncoAlert 🚨 @CD_AACR Academic Recap Activity & Safety of TAK7⃣8⃣8⃣ in #NSCLC w/ #EGFR mutation🧬 Discussed by @OncoAl…
RT @jillfeldman4: Great summary by @StephenVLiu on TAK788 for people with #NSCLC #Exon20 #LCSM https://t.co/PLwbE5cFJf
RT @OncoAlert: The @OncoAlert 🚨 @CD_AACR Academic Recap Activity & Safety of TAK7⃣8⃣8⃣ in #NSCLC w/ #EGFR mutation🧬 Discussed by @OncoAl…
RT @OncoReporte: No te pierdas esta nueva colaboración entre @OncoAlert 🚨 y nuestros amigos de @CD_AACR Esta semana hablamos #Cancer de p…
RT @jillfeldman4: Great summary by @StephenVLiu on TAK788 for people with #NSCLC #Exon20 #LCSM
RT @ElizSMcKenna: The first @OncoAlert - @CD_AACR Academic Recap is up!! @StephenVLiu discusses the recently published phase 1/2 trial of m…
Superb 2 minute recap of mobocertinib highlights, @StephenVLiu! @Exon20Group hopes mobo will become/remain a very important drug for tx-naive pts; as an addition to pem/carbo; as post-plat 2nd-line; as superior to doce/ram any time; and for heavily pretre
RT @weoncologists: The @OncoAlert 🚨 @CD_AACR Academic Recap Great paper on #NSCLC by @RielyMD & Team Amazing Discussion by @StephenVLiu…
RT @OncoAlert: The @OncoAlert 🚨 @CD_AACR Academic Recap Activity & Safety of TAK7⃣8⃣8⃣ in #NSCLC w/ #EGFR mutation🧬 Discussed by @OncoAl…
Great summary by @StephenVLiu on TAK788 for people with #NSCLC #Exon20 #LCSM
RT @ElizSMcKenna: The first @OncoAlert - @CD_AACR Academic Recap is up!! @StephenVLiu discusses the recently published phase 1/2 trial of m…
RT @ElizSMcKenna: The first @OncoAlert - @CD_AACR Academic Recap is up!! @StephenVLiu discusses the recently published phase 1/2 trial of m…
RT @ElizSMcKenna: The first @OncoAlert - @CD_AACR Academic Recap is up!! @StephenVLiu discusses the recently published phase 1/2 trial of m…
RT @OncoAlert: The @OncoAlert 🚨 @CD_AACR Academic Recap Activity & Safety of TAK7⃣8⃣8⃣ in #NSCLC w/ #EGFR mutation🧬 Discussed by @OncoAl…
RT @weoncologists: The @OncoAlert 🚨 @CD_AACR Academic Recap Great paper on #NSCLC by @RielyMD & Team Amazing Discussion by @StephenVLiu…
The @OncoAlert 🚨 @CD_AACR Academic Recap Great paper on #NSCLC by @RielyMD & Team Amazing Discussion by @StephenVLiu PAPER FREE TO DOWNLOAD for 1⃣WEEK‼️ Link to paper: https://t.co/XDxDmiRtlV
RT @ElizSMcKenna: The first @OncoAlert - @CD_AACR Academic Recap is up!! @StephenVLiu discusses the recently published phase 1/2 trial of m…
RT @minhantan: TAK-788 (mobocertinib) shows 43% response rate in Phase I/II dose escalation trial in patients with diverse EGFR exon 20 mut…
RT @OncoAlert: The @OncoAlert 🚨 @CD_AACR Academic Recap Activity & Safety of TAK7⃣8⃣8⃣ in #NSCLC w/ #EGFR mutation🧬 Discussed by @OncoAl…
RT @OncoAlert: The @OncoAlert 🚨 @CD_AACR Academic Recap Activity & Safety of TAK7⃣8⃣8⃣ in #NSCLC w/ #EGFR mutation🧬 Discussed by @OncoAl…
RT @minhantan: TAK-788 (mobocertinib) shows 43% response rate in Phase I/II dose escalation trial in patients with diverse EGFR exon 20 mut…
RT @OncoAlert: The @OncoAlert 🚨 @CD_AACR Academic Recap Activity & Safety of TAK7⃣8⃣8⃣ in #NSCLC w/ #EGFR mutation🧬 Discussed by @OncoAl…
TAK-788 (mobocertinib) shows 43% response rate in Phase I/II dose escalation trial in patients with diverse EGFR exon 20 mutations.
RT @OncoAlert: The @OncoAlert 🚨 @CD_AACR Academic Recap Activity & Safety of TAK7⃣8⃣8⃣ in #NSCLC w/ #EGFR mutation🧬 Discussed by @OncoAl…
RT @OncoAlert: The @OncoAlert 🚨 @CD_AACR Academic Recap Activity & Safety of TAK7⃣8⃣8⃣ in #NSCLC w/ #EGFR mutation🧬 Discussed by @OncoAl…
RT @ElizSMcKenna: The first @OncoAlert - @CD_AACR Academic Recap is up!! @StephenVLiu discusses the recently published phase 1/2 trial of m…
RT @ElizSMcKenna: The first @OncoAlert - @CD_AACR Academic Recap is up!! @StephenVLiu discusses the recently published phase 1/2 trial of m…
Ck out the latest collaboration from.@OncoAlert w/@StephenVLiu ! .@oncologynursing
RT @ElizSMcKenna: The first @OncoAlert - @CD_AACR Academic Recap is up!! @StephenVLiu discusses the recently published phase 1/2 trial of m…
RT @OncoAlert: The @OncoAlert 🚨 @CD_AACR Academic Recap Activity & Safety of TAK7⃣8⃣8⃣ in #NSCLC w/ #EGFR mutation🧬 Discussed by @OncoAl…
RT @OncoAlert: The @OncoAlert 🚨 @CD_AACR Academic Recap Activity & Safety of TAK7⃣8⃣8⃣ in #NSCLC w/ #EGFR mutation🧬 Discussed by @OncoAl…
No te pierdas esta nueva colaboración entre @OncoAlert 🚨 y nuestros amigos de @CD_AACR Esta semana hablamos #Cancer de pulmón Activity&Safety of TAK788 in #NSCLC w/ #EGFR mutation Con nuestro Colega @StephenVLiu El articulo es gratis por1⃣sema
RT @ElizSMcKenna: The first @OncoAlert - @CD_AACR Academic Recap is up!! @StephenVLiu discusses the recently published phase 1/2 trial of m…
RT @OncoAlert: The @OncoAlert 🚨 @CD_AACR Academic Recap Activity & Safety of TAK7⃣8⃣8⃣ in #NSCLC w/ #EGFR mutation🧬 Discussed by @OncoAl…
RT @OncoAlert: The @OncoAlert 🚨 @CD_AACR Academic Recap Activity & Safety of TAK7⃣8⃣8⃣ in #NSCLC w/ #EGFR mutation🧬 Discussed by @OncoAl…
RT @ElizSMcKenna: The first @OncoAlert - @CD_AACR Academic Recap is up!! @StephenVLiu discusses the recently published phase 1/2 trial of m…
The first @OncoAlert - @CD_AACR Academic Recap is up!! @StephenVLiu discusses the recently published phase 1/2 trial of mobocertinib in EGFR exon 20-mutant #lungcancer by @RielyMD and colleagues.
RT @OncoAlert: The @OncoAlert 🚨 @CD_AACR Academic Recap Activity & Safety of TAK7⃣8⃣8⃣ in #NSCLC w/ #EGFR mutation🧬 Discussed by @OncoAl…
RT @OncoAlert: The @OncoAlert 🚨 @CD_AACR Academic Recap Activity & Safety of TAK7⃣8⃣8⃣ in #NSCLC w/ #EGFR mutation🧬 Discussed by @OncoAl…
The @OncoAlert 🚨 @CD_AACR Academic Recap Activity & Safety of TAK7⃣8⃣8⃣ in #NSCLC w/ #EGFR mutation🧬 Discussed by @OncoAlert Colleague & #LungCancer Faculty @StephenVLiu 👨⚕️🇺🇸 #LCSM Paper available for FREE for1⃣week https://t.co/tY9dcuvTZL C
RT @NatRevClinOncol: in phase I/II trial involving pts with EGFR mut, EGFR inh mobocertinib was deemed tolerable and led to ORR of 43% and…
in phase I/II trial involving pts with EGFR mut, EGFR inh mobocertinib was deemed tolerable and led to ORR of 43% and mPFS of 7.3 months https://t.co/KIAvVjQANo preclinical results w mobocertinib also published https://t.co/NheLE4uLSW
Exciting new NSCLC clinical results of an irreversible EGFR kinase inhibitor specifically designed for exon 20 mutations... unfortunately but expectedly the drug completely loses activity in presence of the C797S secondary resistance mutation https://t.co/
Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer https://t.co/VIlq8cu7zE
RT @ElizSMcKenna: Mobocertinib (TAK-788): A targeted inhibitor of #EGFR #exon20 insertion mutants in non-small cell #lungcancer @TakedaOnco…
RT @BIDThoracicOnc: The preclinical development of mobocertinib (TAK-788) has been published concurrently: https://t.co/5GolgMWOmy
The preclinical development of mobocertinib (TAK-788) has been published concurrently: https://t.co/5GolgMWOmy
Just published #OnlineFirst— Mobocertinib (TAK-788): A targeted inhibitor of #EGFR #exon20 insertion mutants in non-small cell #lungcancer. @TakedaOncology #NSCLC https://t.co/9Zi7beDiJv https://t.co/ZkpCXSlD3g
Mobocertinib (TAK-788): A targeted inhibitor of #EGFR #exon20 insertion mutants in non-small cell #lungcancer @TakedaOncology #NSCLC #drugdevelopment https://t.co/dHrGQ4PMuD